Candel Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
CADL$9.35-1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands, except share amounts)
| COMMON STOCK · TREASURY STOCK · ADDITIONALPAID-IN · ACCUMULATED · STOCKHOLDERS’ | |||||||
|---|---|---|---|---|---|---|---|
| SHARES | AMOUNT | SHARES | AMOUNT | CAPITAL | DEFICIT | EQUITY | |
| Balance, December 31, 2025 | 55,020,911 | $550 | (122,608) | $(448) | $282,207 | $(230,387) | $51,922 |
| Options exercised | 10,937 | — | — | — | 28 | — | 28 |
| Stock-based compensation | — | — | — | — | 1,579 | — | 1,579 |
| Change in fair value of NC Ohio Trust Warrants | — | — | — | — | (127) | — | (127) |
| Issuance of common stock in public offering, net of issuance costs of $6.5 million | 18,348,624 | 183 | — | — | 93,305 | — | 93,488 |
| Net loss | — | — | — | — | — | (8,861) | (8,861) |
| Balance, March 31, 2026 | 73,380,472 | $733 | (122,608) | $(448) | $376,992 | $(239,248) | $138,029 |
| COMMON STOCK · TREASURY STOCK · ADDITIONALPAID-IN · ACCUMULATED · STOCKHOLDERS’ | |||||||
|---|---|---|---|---|---|---|---|
| SHARES | AMOUNT | SHARES | AMOUNT | CAPITAL | DEFICIT | EQUITY | |
| Balance, December 31, 2024 | 46,933,088 | $469 | (122,608) | $(448) | $258,511 | $(192,205) | $66,327 |
| Options exercised | 118,356 | 1 | — | — | 245 | — | 246 |
| Stock-based compensation | — | — | — | — | 798 | — | 798 |
| Restricted stock unit vesting | 330,779 | 3 | — | — | (3) | — | — |
| Change in fair value of NC Ohio Trust Warrants | — | — | — | — | (484) | — | (484) |
| Sale of common stock through at-the-market offerings, net of issuance costs | 40,334 | 1 | — | — | 383 | — | 384 |
| Exercise of pre-funded warrants | 1,947,192 | 19 | — | — | (19) | — | — |
| Issuance costs related to common stockand accompanying pre-fundedwarrants in public offering | — | — | — | — | 25 | — | 25 |
| Net income | — | — | — | — | — | 7,379 | 7,379 |
| Balance, March 31, 2025 | 49,369,749 | $493 | (122,608) | $(448) | $259,456 | $(184,826) | $74,675 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.